Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women

G. Christodoulacos, C Panoulis, Constantinos Panoulis, D. Botsis, D. Rizos, Demetrios Rizos, D Kassanos, Dimitrios Kassanos, G. Creatsas, George Creatsas
Maturitas · 2002 · vol. 42(1) , pp. 77–84 · doi:10.1016/s0378-5122(02)00027-0 · PMID:12020983 · W2036755428
RCT OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This study used transvaginal sonography to monitor the uterine effects of raloxifene and a continuous combined hormone replacement therapy in postmenopausal women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To study the effect of 17beta-estradiol+norethisterone acetate and raloxifene on the endometrium and uterine volume in postmenopausal women. METHODS: Patients were randomly assigned to 17beta-estradiol 2 mg+norethisterone acetate 1mg (E2+NETA) daily (n=90) or raloxifene HCl 60 mg (Evista) daily (n=43). Transvaginal sonography was done at baseline and at 6, 12 and 18 months, and at 6 and 12 months in-patients treated with E2+NETA and EVISTA respectively. Patients were asked to record bleeding-spotting episodes. Whenever required patients were referred for hysteroscopy+/-biopsy of the endometrium. RESULTS: Patients under E2+NETA had a higher bleeding-spotting incidence (48.6%) compared with EVISTA (7.7%). Endometrial thickness increased significantly under E2+NETA as compared with baseline; however, at end point thickness reverted to baseline values. Evista had a non-stimulatory effect on the endometrium. Changes in uterine volume were not statistically significant. CONCLUSIONS: Both treatment regimens provided comparable uterine safety. However, raloxifene exhibited a more favorable safety profile on the uterus as expressed in the bleeding-spotting incidence and the effect on endometrial thickness and uterine volume. Transvaginal sonography appears to be a dependable method for monitoring the effect of treatment on the uterus.

My notes (saved in your browser only)

MeSH descriptors

Estradiol Estrogen Replacement Therapy Norethindrone Norethindrone Raloxifene Hydrochloride Selective Estrogen Receptor Modulators Uterus Administration, Oral Adult Drug Administration Schedule Endometrium Endometrium Endometrium Estradiol Estradiol Female Humans Middle Aged Norethindrone Norethindrone

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (1)

References (24)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-11T06:22:51.059792+00:00
pubmed
last seen: 2026-10-08T21:00:31.392641+00:00
unpaywall
last seen: 2026-10-31T06:28:23.984441+00:00
License: CC0 · commercial use OK